PMVP

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:PMVP

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/11	05:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/06/07	21:32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/30	20:00	GlobeNewswire Inc.	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/29	20:00	Business Wire	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/29	20:00	GlobeNewswire Inc.	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/09	21:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/09	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/09	21:00	GlobeNewswire Inc.	PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/27	21:00	GlobeNewswire Inc.	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/19	05:01	GlobeNewswire Inc.	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/01	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/01	06:01	GlobeNewswire Inc.	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/02/26	22:00	GlobeNewswire Inc.	PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/24	23:01	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/23	06:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/23	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/19	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/19	06:01	GlobeNewswire Inc.	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/12	06:18	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/06	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/06	06:01	GlobeNewswire Inc.	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/11/09	22:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/11/09	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/11/09	22:00	GlobeNewswire Inc.	PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/13	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/13	01:30	GlobeNewswire Inc.	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/12	05:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/12	01:00	GlobeNewswire Inc.	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/09/21	05:05	GlobeNewswire Inc.	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/09/19	05:26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc